Vimarsana
Biggest News Aggregation in the World

Michael Lampe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Lampe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Lampe Today - Breaking & Trending Today

Foghorn Therapeutics Announces CFO Departure - Vimarsana News

Foghorn Therapeutics Announces CFO Departure

CAMBRIDGE, Mass., Jan. 03, 2024 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting - Vimarsana News

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 01, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM ... - Vimarsana News

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM ...

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs - Vimarsana News

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

CAMBRIDGE, Mass., Oct. 24, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...

Leading Independent Proxy Advisory Firm ISS Recommends - Vimarsana News

Leading Independent Proxy Advisory Firm ISS Recommends

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (